The State of Radiopharmaceuticals 2026
Q1 2026
The definitive operating-reality assessment of the global radiopharmaceutical sector. A systems-level deconstruction from atomic physics through geopolitics, manufacturing, regulation, logistics, and last-mile hospital infrastructure. Built from executive search mandate intelligence across 50+ radiopharma organisations.
Authored by
Byron Fitzgerald, Founder, ProGen Search
What This Report Covers
Built from executive search mandate intelligence across 50+ radiopharma organisations. This is not a clinical pipeline tracker, a market-sizing exercise, or an investor pitch. It is a systems-level deconstruction of the radiopharmaceutical industry covering isotope supply-chain fragility, the alpha emitter transition, manufacturing scale-up constraints, NRC/FDA regulatory divergence, radiation-qualified talent scarcity, and capital reallocation.
Each chapter was subjected to three independent deep-research sweeps across regulatory filings, industry datasets, clinical registries, and proprietary intelligence, then distilled through structured analytical synthesis to surface hidden patterns and second-order implications.
Buy this report
From
$1,495
Three licence tiers for individuals, teams, and institutions.
Individual
Single reader
$1,495
Enterprise
One operating company
$5,995
Investor & Bank Licence
Banks and institutional investors
$14,995
Chapters
The Inflection Point
Capital flows, the great consolidation, and the chasm between narrative and operating reality.
The Tyranny of the Half-Life
Why nuclear physics, not pharmacology, governs every operational decision in this industry.
The Isotope Wars
Lutetium-177, actinium-225, lead-212. Where the atoms come from and who controls them.
The Illusion of Preparedness
Announced capacity vs execution-ready capacity. Why most facility press releases overstate reality.
The Architecture of Time
Logistics, hospital readiness, and the failure chains by which doses die between factory and patient.
The Paradox of Readiness
The talent ceiling. Why human capital, not capital, is the binding constraint.
The Regime Change in Pharmaceutical Value
What the market is mispricing. Infrastructure premiums, false comparables, and structural repricing.
The Archetype Framework
Seven competitive archetypes. Vertically integrated giants, pure-play developers, specialist CDMOs, hybrids, regional nodes, picks-and-shovels, last-mile integrators.
The Analytical Blind Spot
Fifteen misconceptions and six broken frameworks. The corrected lens for evaluating this sector.
From Analysis to Forecast
Twelve, twenty-four, thirty-six, and forty-eight month forecasts. Early-warning indicators. Action map for operators, investors, and builders.
From the report
$15B+
Deployed in radiopharma M&A in 2025 alone. Over 80% bundled manufacturing infrastructure, not molecules.
The factory has replaced the molecule as the competitive moat. Big Pharma is paying multi-billion-dollar premiums for hot-cell capacity, isotope contracts, and licensed teams. Asset-light is dead in this sector.
Who reads this and what they use it for
Investment bankers and analysts
Pricing the manufacturing premium into deal models. Stress-testing management projections against operating reality.
Pharma BD and strategy
Stress-testing partnership theses before term sheets. Identifying which targets carry hidden infrastructure risk.
Institutional investors and VCs
Allocating across radiopharma names with a structural read on capacity, talent, and capital flow that public filings do not show.
Byron Fitzgerald, Founder, ProGen Search
About the Author
Byron Fitzgerald
Byron Fitzgerald has spent more than 15 years in life sciences executive search and founded ProGen Search in 2024. He is a three-time founder, having previously bootstrapped a specialist consultancy from a standing start to 36 consultants. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. Through retained search and commissioned intelligence work, he speaks daily with the C-suite, investors, PE/VC partners, and BD leaders who set strategy across this sector.
His published market intelligence on radiopharmaceutical manufacturing, CDMO capacity constraints, ADC execution risk, and advanced modality talent markets is read by C-suite leaders, institutional investors, and board members globally.
Choose your access
Three tiers, calibrated to how you intend to use the work.
Individual
$1,495
Single reader. Personal use within one company.
- PDF delivered immediately
- 84 pages across 10 chapters
- Single-user license
Enterprise
$5,995
Distribute across one operating company or strategy team.
- Everything in Individual
- Unlimited internal seats within one entity
- Internal redistribution and excerpting rights
Investor & Bank Licence
$14,995
Investment banks, institutional investors, and consulting firms citing the report in client materials.
- Everything in Enterprise
- Citation rights in client-facing reports and pitches
- Multi-fund or multi-team distribution
By completing your purchase, you agree to our Purchase Terms.
Frequently asked questions
How is the report delivered?
PDF delivered immediately after purchase to the email address you use at checkout. The file is 84 pages across 10 chapters, designed to be read end to end or referenced by section. Any delivery issue, email byron.fitzgerald@progensearch.com directly.
What is the refund policy?
Purchases are non-refundable once access has been granted. Because the report is a digital product delivered immediately on completion of payment, by completing your purchase you expressly request immediate access and acknowledge that any cancellation or cooling-off right that would otherwise apply is waived to the fullest extent permitted by applicable law.
How do multi-seat and team licences work?
The Individual licence is for a single reader within one company. The Enterprise licence covers unlimited internal seats inside one operating entity, including internal redistribution and excerpting. The Investor and Bank licence extends those rights to multiple funds, teams, or client-facing materials.
Can I cite the report in client-facing work?
Individual and Enterprise licences are for internal use only. The Investor and Bank licence permits citation of specific charts and findings in client-facing reports, pitches, and investor memos, with attribution to ProGen Search. Direct lifting of full chapters is not permitted under any tier.
How do I expense or invoice the report through procurement?
Email byron.fitzgerald@progensearch.com with the entity name, billing address, VAT or tax ID if applicable, and the tier required. We will issue a formal invoice and arrange payment by bank transfer or credit card. Most procurement turnarounds settle within five business days.
Ready when you are.
If your team is making radiopharma decisions in 2026, the cost of getting this wrong is many multiples of $1,495. The report exists to make that decision easier.
View pricing